Professor Min Huang, Principal Investigator

Major research interest：
Our team mainly focuses on pharmacokinetics, pharmacogenomics, pharmacometabolomics, and clinical pharmacology.  In the past few years, the team has been active in racial and inter-individual difference in genetic polymorphism of drug metabolizing enzymes/transporters, personalized medicine and pharmacotherapy, nuclear receptors/enzymes/transporters mediated drug-drug interaction and herb-drug interaction. The team also has strong research background in preclinical and clinical pharmacokinetics, Phase I clinical trial, and bioavailability/bioequivalence evaluation. In the past 30 years, they have accomplished about 300 preclinical pharmacokinetic evaluations, Phase I clinical trials, and BA/BE evaluations.

Facilities:
The lab was equiped with UPLC, LC-MS/MS, QTOF-MS platforms for pharmacokinetics and pharmacometabolomics studies, and  SEQUENOM MassArray system for pharmacogenomics study. The team consists of three full professors, three associate professors, three lecturers, and six technicians. Together with the Affiliated Tumor Hospital and the First Affiliated Hospital of SYSU, they established the Phase I Clinical Trial Centre and passed the inspection organized by SFDA. With the financial support by the National Major Projects from the Science and Technology Ministry of China, they have established a national clinical pharmacokinetics evaluation platform with the affiliated hospitals at SYSU. They have also developed a series of in vitro and in vivo pharmacokinetic techniques on molecular or cellular level for high-throughput ADME screening of drug discovery, which enable the lab to move and expand to a more molecular and high throughput focus.

Main goals:
To establish a key laboratory in Pharmacogenomics and Pharmacokinetics, and bridge bench research in PK and PGx to clinical bedside.